Blood Test Accurately Predicts Five

Key Points:

• A new international study involving 2,684 cognitively unimpaired older adults found that individuals with very high baseline blood levels of the biomarker p-tau217 have a 38% absolute risk of developing cognitive impairment within 5 years, increasing to 78% within 10 years.
• The predictive power of p-tau217 operates independently of other known Alzheimer's risk factors, such as amyloid-beta plaques detected by PET scans and APOE4 genetics, making it a robust biomarker for identifying high-risk individuals.
• Despite its accuracy, current clinical guidelines do not recommend p-tau217 blood testing for asymptomatic individuals due to the lack of approved disease-modifying treatments at preclinical stages; behavioral and preventative measures remain the standard advice.
• The primary immediate application of p-tau217 testing is to screen and select candidates for Alzheimer's disease prevention clinical trials, aiming to intervene early when treatments may be most effective.
• Researchers aim to develop p-tau217 testing into a routine screening tool analogous to cholesterol tests in cardiovascular health, enabling proactive monitoring and early intervention to prevent cognitive decline.